Boston Scientific Corporation revenue by segment BSX

Annual Quarterly

Boston Scientific Corporation splits its revenue 2 ways in its filings. By operating segments, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Cardiovascular at $3.4 billion, 66% of the total. By sales mix, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Interventional Cardiology Therapies at $1.3 billion, 25% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	21,070	5,138	5,442	5,203	5,286	5,065	5,061	4,663	4,561
Operating segments
Cardiovascular	—	3,406 +1.9% share 66.3%	3,624 +8.3% share 66.6%	3,503 +13.5% share 67.3%	—	3,343 share 66.0%	3,345 share 66.1%	3,085 share 66.2%	—
Medsurg	—	1,733 +0.6% share 33.7%	1,818 +5.9% share 33.4%	1,701 +7.9% share 32.7%	—	1,722 share 34.0%	1,716 share 33.9%	1,577 share 33.8%	—
Sales mix
Interventional Cardiology Therapies	—	1,273 +12.2% share 24.8%	1,333 +13.2% share 24.5%	1,244 +10.7% share 23.9%	—	1,135 share 22.4%	1,178 share 23.3%	1,124 share 24.1%	—
Electrophysiology EP	—	816 -5.7% share 15.9%	916 share 16.8%	905 +24.0% share 17.4%	—	865 share 17.1%	—	730 share 15.7%	—
Global Endoscopy Endo Reporting Unit	—	741 -0.8% share 14.4%	793 share 14.6%	736 +9.4% share 14.1%	—	747 share 14.7%	—	673 share 14.4%	—
Global Urologyand Pelvic Health Reporting Unit	—	661 -3.1% share 12.9%	684 +1.2% share 12.6%	646 +2.1% share 12.4%	—	682 share 13.5%	676 share 13.4%	633 share 13.6%	—
Cardiac Rhythm Management	—	568 -1.7% share 11.1%	585 -0.8% share 10.7%	578 +0.0% share 11.1%	—	578 share 11.4%	590 share 11.7%	578 share 12.4%	—
Watchman	—	482 -5.9% share 9.4%	507 +4.3% share 9.3%	506 +19.1% share 9.7%	—	512 share 10.1%	486 share 9.6%	425 share 9.1%	—
Global Neuromodulation Nm Reporting Unit	—	331 +13.0% share 6.4%	341 +12.5% share 6.3%	318 +17.3% share 6.1%	—	293 share 5.8%	303 share 6.0%	271 share 5.8%	—
Interventional Oncology And Embolization	—	267 +5.5% share 5.2%	283 +12.7% share 5.2%	268 +17.5% share 5.2%	—	253 share 5.0%	251 share 5.0%	228 share 4.9%	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as: BSX (NYSE)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Marlborough, MA
SEC filer status: Large accelerated filer
SEC CIK: 885725

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.